系统性硬化症患者皮肤与血清中IL-16表达升高
该研究采用免疫组化分析SSc患者受累皮肤中IL-16的数量与定位,并用ELISA检测血清IL-16水平,进而验证其与临床症状的相关性。结果显示dcSSc患者皮肤IL-16阳性细胞比例高于lcSSc患者,SSc患者血清IL-16水平显著高于健康对照,且升高的血清IL-16与dcSSc分类、皮肤评分及红斑和色素沉着相关。
要点
- dcSSc患者皮肤IL-16阳性细胞比例显著高于lcSSc患者。
- SSc患者血清IL-16水平显著高于健康对照。
- 血清IL-16升高与dcSSc分类、皮肤评分及红斑和色素沉着相关。
核心结论
- 皮肤IL-16区域上调不仅与皮肤硬化相关,也与全身性IL-16激活相关。
- IL-16可能参与SSc发病机制。
- 血清IL-16水平可能作为判断皮肤硬化严重程度的生物标志物。
- 抑制IL-16激活可能对治疗SSc有效。
研究设计与样本
- 采用免疫组化分析SSc患者受累皮肤中IL-16的数量与定位。
- 采用ELISA检测SSc患者血清IL-16水平。
- 验证血清IL-16水平与SSc患者临床症状的相关性。
主要发现
- 皮肤中IL-16表达于毛细血管周围淋巴细胞。
- dcSSc患者皮肤IL-16阳性细胞比例高于lcSSc患者(43.9 vs 29.1%,P < 0.05)。
- SSc患者血清IL-16水平显著高于健康对照(297.0 vs 194.9 pg/ml,P < 0.05)。
- SSc患者血清IL-16升高与dcSSc分类、皮肤评分及红斑和色素沉着相关。
关键数值与推荐
- dcSSc与lcSSc皮肤IL-16阳性细胞比例分别为43.9%与29.1%(P < 0.05)。
- SSc患者与健康对照血清IL-16水平分别为297.0与194.9 pg/ml(P < 0.05)。
临床怎么用
- 血清IL-16水平可能用于辅助判断SSc皮肤硬化严重程度。
- IL-16激活可能作为SSc治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is an autoimmune disease with chronic and persistent inflammation in its pathogenesis. To examine the expression pattern of IL-16 in SSc lesions, the serum concentration of IL-16 in SSc patients and the relationship between serum IL-16 levels and the clinical symptoms of SSc were investigated. METHODS: Using immunohistochemical analysis, we examined the quantity and localization of IL-16 in affected skin obtained from SSc patients. We also measured serum levels of IL-16 in SSc patients using an ELISA. We then validated the correlation between serum IL-16 levels and clinical symptoms in patients with SSc. RESULTS: In the skin, IL-16 was expressed on the lymphocytes around the capillaries. Furthermore, the proportion of IL-16-positive cells was statistically higher in patients with dcSSc than in those with lcSSc patients (43.9 vs 29.1%, P < 0.05). The serum IL-16 levels in SSc patients were statistically significant elevated compared with healthy controls (297.0 vs 194.9 pg/ml, P < 0.05). Increased serum IL-16 levels in SSc patients were correlated with the proportion classified as dcSSc, skin score and the presence of cutaneous symptoms of erythema and pigmentation. CONCLUSION: The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. IL-16 may play a role in the pathogenesis of SSc. Moreover, serum IL-16 levels may be useful as a biomarker for determining the severity of the skin sclerosis. Inhibiting IL-16 activation may be effective in treating SSc.
引用
- Kawabata K, Makino T, Makino K, et al. IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 31377804. doi:10.1093/rheumatology/kez318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。